Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Behavioral Inflexibility in Autism
NCT05999240Phase 2Recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pimavanserin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoints: Impact of a single dose of pimavanserin 34 mg versus placebo and Pimavanserin for treatment of restricted/repetitive behavior in ASD at 6 weeks. Started Oct 2025; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05999240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999240.